Surmodics, Inc. (NASDAQ:SRDX) Shares Bought by Diametric Capital LP

Diametric Capital LP lifted its holdings in shares of Surmodics, Inc. (NASDAQ:SRDX - Free Report) by 89.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 20,437 shares of the company's stock after acquiring an additional 9,659 shares during the quarter. Diametric Capital LP owned about 0.14% of Surmodics worth $809,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Gardner Lewis Asset Management L P boosted its position in shares of Surmodics by 23.5% in the fourth quarter. Gardner Lewis Asset Management L P now owns 262,878 shares of the company's stock worth $10,410,000 after buying an additional 49,944 shares during the period. Boussard & Gavaudan Investment Management LLP acquired a new position in Surmodics during the 4th quarter worth approximately $3,899,000. Norges Bank purchased a new position in Surmodics in the 4th quarter worth approximately $1,251,000. JPMorgan Chase & Co. grew its position in Surmodics by 20.1% in the fourth quarter. JPMorgan Chase & Co. now owns 50,990 shares of the company's stock valued at $2,019,000 after acquiring an additional 8,520 shares in the last quarter. Finally, Mint Tower Capital Management B.V. purchased a new stake in shares of Surmodics during the fourth quarter valued at approximately $1,507,000. 96.63% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on SRDX shares. Lake Street Capital raised shares of Surmodics from a "hold" rating to a "buy" rating and set a $43.00 price target for the company in a report on Friday, March 7th. Needham & Company LLC restated a "hold" rating on shares of Surmodics in a research note on Thursday, January 30th. Finally, StockNews.com assumed coverage on Surmodics in a research report on Monday, February 3rd. They set a "hold" rating on the stock. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $50.00.

Remove Ads

Surmodics Stock Down 2.6 %

Shares of SRDX stock traded down $0.79 during trading hours on Friday, hitting $29.32. 237,968 shares of the company were exchanged, compared to its average volume of 280,175. The stock has a market capitalization of $419.16 million, a price-to-earnings ratio of -29.03 and a beta of 1.30. Surmodics, Inc. has a one year low of $25.17 and a one year high of $42.44. The business's 50-day simple moving average is $32.16 and its two-hundred day simple moving average is $36.43. The company has a debt-to-equity ratio of 0.26, a quick ratio of 4.29 and a current ratio of 5.45.

Surmodics (NASDAQ:SRDX - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported ($0.04) EPS for the quarter, topping analysts' consensus estimates of ($0.08) by $0.04. Surmodics had a negative return on equity of 4.39% and a negative net margin of 11.48%. Sell-side analysts predict that Surmodics, Inc. will post 0.2 EPS for the current fiscal year.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).